OmniAb, Inc. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing presents a dichotomy between rapid milestone-driven growth and a persistent structural deficit. While the 247% revenue increase is a powerful signal of platform validation, the reliance on one-off payments makes the current growth rate an unreliable predictor of future performance. The company has successfully reduced its quarterly burn, but it remains dependent on external funding or sporadic milestone hits to sustain operations. Ultimately, the investment thesis hinges on whether OmniAb can convert its 409 active programs into a steady stream of royalties and recurring license fees. The current transition toward lower operating expenses is a positive step, but the looming threat of equity dilution and the volatility of milestone revenue suggest that the path to sustained profitability remains fraught with risk. The market must now decide if the company is a maturing technology licensor or a high-burn biotech with a fragile cash runway.